Pharmacotherapeutic monitoring of anastrozole use in patientes with breast cancer

• Autor(a) principal: Rivera, Juan Gonzalo Bardález
• Data de Publicação: 2023
• Outros Autores: Quemel, Gleicy Kelly China, Abrantes, Gisely France, Mendonça, Gisele dos Santos, Sousa, Letícia Teixeira de
• Tipo de documento: Artigo
• Idioma: por
• Título da fonte: Revista JRG de Estudos Acadêmicos
• Texto Completo: http://revistajrg.com/index.php/jrg/article/view/716
• topic: Câncer de mama. Anastrozol. Monitorização farmacoterapêutica; Breast cancer. Anastrazole. Pharmacotherapeutic monitoring

Cancer is a pathology that can develop in the body through the abnormal and disorderly growth of cells. Breast cancer is among the most feared types of cancer that affect women, due to the damage caused by the treatment and the psychological impacts Genetic alterations in the BRCA genes are mainly responsible for the development of this neoplasm. Aromatase inhibitors (AI), which belongs to anastrozole, which is a drug that acts by inhibiting aromatase, the enzyme responsible for converting steroidal hormones into estrogen. However, this drug has certain side effects and may result in poor adherence to treatment. This is an integrative literature review (RIL). Nine articles were found that met the inclusion and exclusion criteria. It is concluded that the participation of the pharmacist interacting with the multidisciplinary team in the oncology sector is of paramount importance. Since, this health professional contributes with numerous advantages for patients, whether in the selection of drugs, in the analysis of prescriptions, in pharmacotherapeutic monitoring and adherence to pharmacological treatment, in drug interactions, improving the relationship between patient and pharmacist. In this way, minimizing prescription errors and accompanying the breast cancer patient during her treatment, avoiding the appearance of adverse effects and therapeutic failures.